NCT00306566
Completed
Phase 1
A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma
ConditionsMalignant Melanoma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Malignant Melanoma
- Sponsor
- Cytos Biotechnology AG
- Locations
- 1
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to provide written informed consent
- •Able and willing to complete all protocol requirements
- •Age: 18 years and older
- •Histological confirmed stage II melanoma
- •HLA-A\*0201 haplotype
- •Expected survival of at least 6 months
- •ECOG performance status of 0 or 1
- •Full recovery from surgery
- •Adequate organ and bone marrow functions
- •Sexually active males should use adequate contraception throughout the study period and 3 months thereafter.
Exclusion Criteria
- •Pregnant or nursing
- •Use of an investigational drug within 30 days before enrolment
- •Active malignancy in the 5 years prior to enrollment other than melanoma, basal cell carcinoma or cervical carcinoma in situ.
- •Major surgery within 4 weeks prior to enrollment.
- •Current use of an immunosuppressive drug or any concomitant medication that could potentially interfere with the study drug (e.g. steroids, antihistamine drugs; topical or inhalational steroids are permitted).
- •Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious, or neurological disorders.
- •Serum tests positive for HIV, HBV, HCV.
- •Active autoimmune diseases or severe allergies.
- •Current diagnosis or history of relevant and severe psychiatric disorder that compromises the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol or to complete the study.
- •Blood donation or loss of \> 500mL within 8 weeks prior to inclusion.
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma PatientsMelanomaNCT00559026Istituto Superiore di Sanità10
Terminated
Phase 1
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic MelanomaMetastatic MelanomaNCT01216436Duke University2
Withdrawn
Phase 2
Study of Immune Responses in Patients With Metastatic MelanomaMetastatic MelanomaNCT01416844Providence Health & Services
Completed
Phase 2
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma PatientsMalignant MelanomaNCT00651703Cytos Biotechnology AG21
Terminated
Phase 2
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCMelanomaNCT01437605H. Lee Moffitt Cancer Center and Research Institute14